Doctor of Podiatric Medicine Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Mica Murdoch

Podiatrist, Foot & Ankle Surgery Des Moines, IA Doctor of Podiatric Medicine

NPI 1962639906 CMS profile 135172

1801 Hickman Rd, Des Moines, IA 50314

Open in the dashboard

General payments

$25,453

280 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$1,118

1 holding reported · through program year 2025

Through program year 2025, Mica Murdoch of Des Moines, IA is reported in the CMS Open Payments database as having received $25,453 across 280 general payments and $0 in research payments paid to them. They also declared ownership or investment interests valued at $1,118 across 1 holding.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Podiatrist, Foot & Ankle Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $6,298 30
2024 General $7,969 24
2023 General $1,736 37
2022 General $3,241 35
2021 General $2,116 41
2020 General $835 36
2019 General $3,259 77
2025 Ownership $1,118 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mica Murdoch
  • Podiatrist, Foot & Ankle Surgery median
  • Middle half of Podiatrist, Foot & Ankle Surgery
  • National median

In program year 2025, general payments to Mica Murdoch were reported at $6,298. Among 6,994 Podiatrist, Foot & Ankle Surgery profiles paid that year, the median was $424 and the middle half received between $139 and $1,306.

Show as a table
Year Mica Murdoch Podiatrist, Foot & Ankle Surgery median Middle half National median
2019 $3,259 $389 $118–$1,406 $163
2020 $835 $191 $62–$691 $114
2021 $2,116 $329 $104–$1,341 $132
2022 $3,241 $419 $125–$1,611 $149
2023 $1,736 $377 $128–$1,164 $160
2024 $7,969 $394 $134–$1,168 $164
2025 $6,298 $424 $139–$1,306 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Nvision Biomedical Technologies, Inc. $10,031 12 payments
  2. Vilex in Tennessee, Inc. $5,513 16 payments
  3. Stryker Corporation $2,448 97 payments
  4. restor3d, inc. $1,977 8 payments
  5. TriMed, Inc. $1,618 4 payments
  6. Acera Surgical, Inc. $526 15 payments
  7. Smith+Nephew, Inc. $496 47 payments
  8. Zimmer Biomet Holdings, Inc. $489 12 payments
  9. Medline Industries, Inc. $435 7 payments
  10. DePuy Synthes Sales Inc. $413 10 payments
  11. Other $1,507 52 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,523 258 payments
  2. Consulting Fee $8,413 4 payments
  3. Travel and Lodging $6,353 14 payments
  4. Royalty or License $2,155 3 payments
  5. Education $10 1 payment
Products named General payments · program years 2019–2025
  1. Trigon $7,204 6 payments
  2. HINTERMANN Orthopedics/Orthopedic Surgery $2,278 8 payments
  3. REDEMPTION $1,913 1 payment
  4. Foot/ankle products $1,274 2 payments
  5. HINTERMANN Orthopedics $1,138 4 payments
  6. ANCHORAGE $1,120 44 payments
  7. Subtolar Wedge $863 2 payments
  8. Foot and Ankle $691 2 payments
  9. MEDLINE UNITE $350 4 payments
  10. INBONE $323 8 payments
  11. Other $5,472 223 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 10 drugs

Part D claims

415

Median for Podiatry: 160

Drug cost

$3,525

Median for Podiatry: $2,368

Branded share of claims

5.8%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Diclofenac Sodium Generic 136 $1,041
Gabapentin Generic 69 $665
Pregabalin Generic 50 $453
Terbinafine Hcl Generic 16 $421
Ibuprofen Generic 37 $281
Nabumetone Generic 18 $207
Oxycodone Hcl Generic 50 $186
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 11 $111
Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim Brand 13 $107
Amitriptyline Hcl Generic 15 $54

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 33 billing codes

Paid by Medicare

$18,062

Medicare's payments for the services billed

Medicare patients

80

Average age 68

Services billed

249

43 women, 37 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 63%
Arthritis 51%
Diabetes 34%
Depression 28%
Heart failure 24%
Ischemic heart disease 20%
COPD 19%
Chronic kidney disease 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DALVANCE
  • AbbVie, Inc. $20
$20 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

280 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Podiatrist, Foot & Ankle Surgery in Iowa

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record